There is no current drug interaction between Tivicay and Isentress. This does not mean interactions cannot occur at all. It’s best to consult with a medical specialist to assess your health and determine if this drug combination is good for you.
Tivicay is a highly potent INSTI antiretroviral medicine used to medicate HIV/AIDS. It is used with other antiretroviral meds to prevent HIV from multiplying in the body. Its active ingredient dolutegravir is highly effective in preventing the virus from replicating thus protecting and strengthening the immune function. The healthy immune function enables the patient to fight external infections, live longer, and enjoy a healthier life [1]. It is important to remember, though, that it does not cure HIV.
Isentress (containing the active substance raltegravir) belongs to a group of integrase inhibitor antiretroviral meds that prevent HIV-1 infection from multiplying in the patient’s body [2]. It’s a highly potent med, used as a part of a combination therapy together with other antiretroviral meds in combating the virus and strengthening the immune function. This drug is not a cure for HIV/AIDS, but it helps patients lead longer, healthier lives.
It is safe to co-administer these two meds as there is no interaction expected [3]. Primarily, Raltegravir is glucuronidated (via UGT1A1) and dolutegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations. This means, that based on metabolism and clearance, there is no clinically significant interaction that might occur. Still, only a professional health care provider can recommend an individually suitable treatment regiment.